Furthermore, the patients with adenocarcinoma having EGFR mutations were 28.2% (169/431), whereas only 5.4% of the patients with squamous cell carcinoma carried EGFR mutations (Table S1). This evidence concerns the gene EGFR and squamous cell carcinoma.